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These are heady times in endocrinology, with the appli-cation of new techniques revolutionizing our under-
standing of the genetic pathophysiology of many syn-
dromes of endocrine deficiency and excess. It seems that
not a month goes by without a new genetic discovery, and
last year’s teaching slides are already looking out of date.
This ferocious pace of progress is uncovering pathways
and potential targets for treatment in many rare condi-
tions. Some discoveries are entirely new genetic causes,
whereas others are known genes in new disease settings.
This situation is analogous to the work of criminologists
using the selfsame genetic techniques to link unsolved
“cold” cases to known culprits via studies of archived
evidence. In the medical setting, similar good clinical de-
tective work is leading to known genetic culprits in other
neuroendocrine tumors being hauled in for interrogation
in connection with their links to pituitary tumors.
In this issue of the JCEM, Dwight et al (1) describe the
occurrence of a pituitary adenoma in the setting of a fa-
milial succinate dehydrogenase subunit A (SDHA) gene
mutation associated with paraganglioma in a first-degree
relative. This finding expands the field of the tumor fea-
tures associated with succinate dehydrogenase subunit
(SDHx) mutations into the pituitary, joining the first re-
port from the Stratakis group (2) that definitively linked a
succinatedehydrogenase subunitD (SDHD) germlinemu-
tation to acromegaly. Also, a case from Spain associated
with a succinate dehydrogenase subunit C (SDHC) germ-
line mutation was reported, although without pituitary
tumoral DNA confirmation (3). Data from the literature
back to1952 thatwere reviewedbyXekouki andStratakis
(4) have included 29 instances of coexisting pituitary ad-
enomas and pheochromocytomas/paragangliomas. Some
modern cases that were negative for existing causative
gene mutations appear to be persuasive for further inves-
tigation of SDHx status (4). Indeed, the clinical impact of
thesemitochondrial proteinabnormalities alreadyencom-
passes a remarkably wide range of tumors from renal cell
cancers to sporadic and syndromic gastrointestinal stro-
mal tumors (Carney triad and Carney-Stratakis syn-
drome) and beyond (5–9). The addition of pituitary ade-
nomas to the expanding phenotype related to inheritable
pheochromocytoma/paraganglioma syndromes is intrigu-
ing and represents both an opportunity and a challenge.
An important area for future study will be to define
whether SDHx mutation-associated pituitary adenomas
have particular features that differentiate them from the
general sporadic population. Clinically relevant pituitary
adenomas occur is about 1 in 1000 people in the general
population, and prolactinomas account for up to two-
thirds of these (10). Pituitary adenomas that occur in rec-
ognized genetic or familial settings account for about 5%
of cases in our experience (11). Most occur in the setting
of familial isolated pituitary adenoma—either with or
without a germline aryl hydrocarbon receptor interacting
protein (AIP) gene mutation—and multiple endocrine
neoplasia (MEN) 1 (11–13). Rarer syndromes like that of
Carney complex due to protein kinase A regulatory sub-
unit 1A (PRKAR1A) mutations or MEN4 due to cyclin-
dependent kinase inhibitor 1B (CDKN1B) genemutations
also feature pituitary adenomas as part of the described
clinical spectrum (14, 15). Large collaborative studies of
pituitary adenomas that occur against these known ge-
netic backgrounds have revealed features related to more
aggressive behavior, which are useful pointers when de-
termining which patients to offer genetic testing to. AIP
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mutations are associated with a very characteristic profile
of pituitary tumors that mainly occur in childhood or ad-
olescence/young adulthood, usually (but not exclusively)
as somatotropinomas that are large, and treatment resis-
tant, and occur most often in males (11, 16). MEN1-re-
lated pituitary adenomas are most frequently (again, not
exclusively) prolactinomas, but are more difficult to con-
trol with medical therapy (13) and may also occur in
young patients (17). Pituitary adenomas that occur in as-
sociation withCDKN1B germline mutations (MEN4), or
with PRKAR1A mutations in Carney complex, don’t ap-
pear to lead to particularly aggressive features.
Considering that more SDHx-mutated pituitary ade-
nomas are likely to be discovered, it would be important
to determine whether they, too, are relatively more ag-
gressive or lead to a particular subtype of adenoma. Tak-
ing into account the Dwight et al study (1) and those of
Xekouki et al (2) and López-Jiménez et al (3), it appears
that SDHxmutations can lead tomultiple pituitary tumor
phenotypes: somatotropinoma, prolactinoma, and non-
functioning adenoma. It is interesting to note that all 3
pituitary adenomasdisplayedaggressive features.Allwere
macroadenomas that required surgery. The nonfunction-
ing adenoma occurred at a relatively young age (30 y),
whereas theprolactinomaoccurred in amale;male sexhas
been previously shown to associate with more aggressive
behavior in prolactinomas (18). The acromegaly case de-
scribed by Xekouki et al (2) in association with an SDHD
mutation had a “giant” (43 mm maximum diameter) in-
vasive adenoma that compressed the optic chiasma that
had a poor response to somatostatin analogs (2). Fasci-
natingly, the hormonal hypersecretion from the soma-
totropinoma appears to have boosted the production of
catecholamines from the patient’s coexisting pheochro-
mocytoma, which strongly expressed the GH receptor.
That this synchronous pathological relationship possibly
led to worsening of the pheochromocytoma adds impetus
to further investigating the role of the pituitary in SDHx-
related disease. Although admittedly this is a tiny sample
of pituitary adenomas, it suggests that mutation-associ-
ated pituitary adenomas, like those related to AIP and
MEN1mutations, might also occupy the more severe end
of the clinical spectrum.
Histopathological studies also promise to provide
greater clarity about the role of SDHx mutations in pitu-
itary tumorigenesis. Like the impressive work done in the
setting of pheochromocytoma/paraganglioma, gastroin-
testinal stromal tumors, and beyond (19–21), SDHx im-
munohistochemical studies of archival tumor blocs after
pituitary neurosurgerywill probably help to identify cases
in which germline mutation testing may be warranted.
Similarly, tumor-based genetic studies will help us under-
stand the pathophysiological role of somatic SDHx mu-
tations in sporadic pituitary tumors. Together, these ap-
proaches could represent a relatively efficient way (in
terms of cost and time) to determine whether SDHx mu-
tations are, in fact, an unexpectedly frequent player in
pituitary tumorigenesis.
From a practical perspective, it is too early to integrate
SDHx mutation analyses into routine clinical genetic in-
vestigation of pituitary tumors. The advent of next gen-
eration sequencing panels has facilitated such expansion
of diagnostic efforts significantly. First, however, we need
to establish the epidemiology of this potential SDHx mu-
tation link topituitary tumor risk inorder to tailor genetic,
hormonal, and imaging screening activities to aid the cli-
nician’s work. Given the extensive collaborative research
networks that exist to study pheochromocytomas and
paragangliomas, this type of epidemiologicalwork should
be feasible (22). As noted in the study by Dwight et al (1),
currentmagnetic resonance imaging screening for carriers
of SDHx mutations does not routinely include the sellar
region. Initial epidemiological work will, therefore, need
to rely on existing clinical information and resurvey of
patients and family members for pituitary disorders.
Given that incidentalomas are a common occurrence in
the pituitary, radiological screening studies will need to
carefully weigh the risk of “overdiagnosis” of clinically
nonrelevant incidental (micro)adenomas and thus avoid
skewing the importance of the pituitary component of this
emergent endocrine neoplasia syndrome (23). TheDwight
et al study (1) and the work of Xekouki et al (2) also serve
as a reminder to all to delve into the medical records and
investigate thosewithatypical or crossoverMEN1/MEN2
phenotypes and, importantly, to make connections be-
tween related patients with this previously unrecognized
association.
Although SDHx mutations like those described by
Dwight et al (1) and othersmay currently be an unfamiliar
cause of inherited pituitary tumor risk, it should not come
entirely as a surprise, given the experiencewithmultiorgan
tumor syndromes like MEN1. In contrast to these highly
penetrant conditions, the true clinical phenotypes of vari-
ably penetrant conditions can be slow to reveal them-
selves. This can cause particular challenges in tumors that
cross the border between traditionally endocrine and non-
endocrine sites, such as the clinical scenarios related to
PTEN mutations (24). Furthermore, recent large-scale
cancer genetic studies provide a new and compelling ar-
gument that cancers may be better understood not by
where they arise but by the genetic mutations/abnormal-
ities that they have in common. Newly minted research
shows remarkable similarities in the genetic makeup of
common cancers affecting different organs such as the en-
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dometrium, ovary, and breast (25). Hence, cancer behav-
ior may be better understood not as a physical geographic
map (site of the primary), but based on shared “cultural”
elements (what genetic language the tumor uses to express
itself). For those working outside of inherited neoplasia
syndromes, this paradigm shift may be a bit jarring. In
contrast, it enjoins us to persevere in the investigation, like
Georges Simenon’s famous detective Commissaire Mai-
gret, and to keep our eyes open for new clues in unlikely
places.
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